Home
Clinical Trials
MK-2870-011/TroFuse

Sacituzumab Tirumotecan as Monotherapy and in Combination With Pembrolizumab in Participants With Triple-Negative Breast Cancer

Short Title: MK-2870-011/TroFuse

Enrollment Status: Recruiting

NCT #: NCT06841354

Specialty Area: Oncology

Condition Studied: Triple Negative Breast Neoplasms

Age Groups: Adult; Older Adult

Phase: III

Study Information

Summary / Purpose

To find out if a new medication called sacituzumab tirumotecan (Sac-TMT)—given alone or with pembrolizumab—can help people with triple-negative breast cancer (TNBC) live longer, feel better, and delay cancer progression compared to standard chemotherapy.

Study Type: Interventional

Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:

Adults 18+ years of age
Diagnosed with triple-negative breast cancer (TNBC) that has spread (metastatic) or cannot be removed with surgery (locally advanced)
No active autoimmune disease

What's Involved

Participation in the study will include:

Intravenous (IV) infusion of Sac-TMT alone or combined with pembrolizumab (an immunotherapy)
CT/MRI scans to monitor your response to treatment
Blood and urine tests to monitor your health and treatment effects
Electrocardiograms (ECGs) to monitor heart function
Questionnaires

Principal Investigator

Lee Schwartzberg, MD

Oncology

A Member of

(775) 982–5000

Renown Hematology/Oncology

View Provider

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Complete Study Details: https://clinicaltrials.gov/study/NCT06841354

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

Health & Wellness eNews